Skip Navigation


NDT Advance Access originally published online on December 1, 2007
Nephrology Dialysis Transplantation 2008 23(1):24-26; doi:10.1093/ndt/gfm827
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/1/24    most recent
gfm827v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gnudi, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gnudi, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Serum intact parathyroid hormone in diabetic patients on haemodialysis: what is the treatment goal?

Luigi Gnudi

Unit for Metabolic Medicine, Department of Diabetes and Endocrinology, Cardiovascular Division, King's College London School of Medicine, Guy's Hospital, King's College London, London, UK

Correspondence and offprint requests to: Luigi Gnudi. Unit for Metabolic Medicine, Department of Diabetes and Endocrinology, Cardiovascular Division, King's College London School of Medicine, Guy's Hospital, King's College London, London, UK. Tel: +44-71881939; E-mail: lugi.gnudi@kcl.ac.uk

Keywords: bone osteodystrophy; diabetes; iPTH; vascular disease

The first 10% of the full text of this article appears below.

In this issue, Murakami et al. describe an interesting association between intact parathyroid hormone (iPTH) circulating levels and glycaemic control in diabetic patients on haemodialysis [1]. The findings describe an inverse correlation between iPTH serum levels and glycaemic control. Specifically, diabetic patients with poor glycaemic control (HbA1c: 7–8%) are characterized by low circulating iPTH, which is conversely found at higher levels in diabetic patients with good glycaemic control (HbA1c: 5–6%).

Both elevated and low circulating iPTH levels have been linked respectively to high and low bone turnover osteodystrophy (or ‘adynamic bone disease’) in patients on haemodialysis [2–6]; despite the fact that iPTH serum levels are considered important for the understanding of the mechanisms leading to renal-related bone disease, changes in iPTH biological action play . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Reiichi Murakami, Shuichi Murakami, Rumi Tsushima, Chiyuki Ueda, Kyoko Mikami, Takanori Ebina, Ryuichiro Kumasaka, Norio Nakamura, and Ken Okumura
NDT 2008 23: 315-320. [Abstract] [FREE Full Text]  

In this issue ...

NDT 2008 23: i. [Extract] [FREE Full Text]